16 patents
Utility
Use of Bremelanotide In Patients with Controlled Hypertension
25 May 23
The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.
Julie Krop, Laura Ann Williams
Filed: 24 Jan 23
Utility
Use of bremelanotide in patients with controlled hypertension
28 Feb 23
The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.
Julie Krop, Laura Ann Williams
Filed: 21 Jan 21
Utility
Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
9 Feb 23
Wei YANG, John H. DODD, Axel METZGER
Filed: 11 Jul 22
Utility
Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides
17 Nov 22
Wei YANG, John H. DODD
Filed: 12 Jul 22
Utility
Uses of Bremelanotide In Therapy for Female Sexual Dysfunction
17 Nov 22
Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Carl Spana, Robert Jordan, Jeffrey D. Edelson
Filed: 14 Jul 22
Utility
Orally Active Melanocortin Receptor-4 Compounds
30 Jun 22
James Bullington, Axel Metzger, John H. Dodd
Filed: 9 Mar 22
Utility
Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
29 Mar 22
Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.
Wei Yang, Yi-Qun Shi
Filed: 13 Jul 20
Utility
Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery
24 Mar 22
Formulations, compositions and methods for delivery of melanocortin receptor-specific peptides, particularly cyclic peptides selective and specific for the melanocortin-1 receptor, to the lumen of the gastrointestinal tract for treatment of melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes of the gastrointestinal tract.
John Harold Dodd, Stephen Kwaku Dordunoo
Filed: 22 Sep 20
Utility
Use of Bremelanotide In Patients with Controlled Hypertension
22 Jul 21
The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.
Julie Krop, Laura Ann Williams
Filed: 21 Jan 21
Utility
Orally Active Melanocortin Receptor-4 Compounds
1 Jul 21
James Bullington, Axel Metzger, John Harold Dodd
Filed: 17 Mar 21
Utility
Uses of Bremelanotide In Therapy for Female Sexual Dysfunction
4 Mar 21
Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
Carl Spana, Robert Jordan, Jeffrey D. Edelson
Filed: 27 Oct 20
Utility
Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy
28 Oct 20
Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.
Wei Yang, Yi-Qun Shi
Filed: 12 Jul 20
Utility
Therapies for Obesity, Diabetes and Related Indications
2 Sep 20
The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
Carl Spana, John H. Dodd, Marie Makhlina
Filed: 18 May 20
Utility
Melanocortin receptor-specific peptide with C-terminal naphthylalanine
13 Jul 20
Wei Yang, Yi-Qun Shi
Filed: 16 Jan 18
Utility
Therapies for obesity, diabetes and related indications
25 May 20
The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
Carl Spana, John H. Dodd, Marie Makhlina
Filed: 2 Oct 17
Utility
Melanocortin receptor-specific peptides
27 Apr 20
Yi-qun Shi, Shubh D Sharma, John H Dodd, Wei Yang, Xin Chen
Filed: 10 Jan 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first